Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Children’s Hospital Medical Center for S&P Vaccine Platform Development
July 20 2022 - 2:00PM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”), a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced that the Company has entered into a Sponsored Research
Agreement (the “SRA”) with Cincinnati Children’s Hospital Medical
Center (“Cincinnati Children’s”) to explore vaccine development of
its norovirus shell and protrusion (S&P) platform for multiple
diseases.
In July 2021, the Company entered an exclusive, global licensing
agreement with Cincinnati Children’s to develop vaccines for
multiple diseases using the medical center’s virus-like particle
(VLP) vaccine platform. Currently, the platform is being utilized
to develop BWV-301 for gastroenteritis caused by norovirus or
rotavirus. Through the SRA, BWV will further fund research into
this platform’s versatility across other diseases, including
influenza and Alzheimer’s disease.
In a recent publication in Nano Research, titled “Bioengineered
psuedovirus nanoparticles displaying the HA1 antigens of influenza
viruses for enhanced immunogenicity,” Cincinnati Children’s
researchers hypothesized that this platform might represent a
method to create novel influenza vaccines. The SRA initiates the
integration of the epitopes of limited variability identified at
The University of Oxford into this S&P platform for vaccine
development.
In addition, the SRA funds Cincinnati Children’s research
analyzing the applicability of this platform to develop a vaccine
for Alzheimer’s disease. Preliminary research indicates the
potential to develop a vaccine to target and inactivate
amyloid-beta, which can accumulate and form plaques commonly
associated with Alzheimer’s disease.
“This agreement is an important step toward developing vaccines
against multiple diseases that affect millions of individuals each
year,” said Ming Tan, Ph.D., Associate Professor in the Division of
Infectious Diseases and principal investigator of the study at
Cincinnati Children’s. “Through this agreement and in collaboration
with BWV, we can continue our research and work toward development
of beneficial vaccines.”
Tan has a financial interest in the virus-like particle (VLP)
vaccine platform technology that Cincinnati Children’s licensed to
Blue Water Vaccines.
“We are very excited to continue our collaboration with
Cincinnati Children’s and fund this research,” said Joseph
Hernandez, Chairman and Chief Executive Officer of Blue Water
Vaccines. “Research from Cincinnati Children’s has shown great
promise for this platform, and we look forward to continuing this
relationship to address significant public health challenges
through effective vaccines.”
Gastroenteritis, influenza, and Alzheimer’s disease all
represent significant global health challenges in illness and
mortality, as well as associated economic loss. Efficacious vaccine
intervention may prove an effective public health intervention and
address such losses on a global scale.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical
Center, and St. Jude Children's Hospital. The company is developing
a universal flu vaccine that will provide protection from all
virulent strains in addition to licensing a novel norovirus (NoV)
S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from Cincinnati Children’s to develop vaccines for
multiple infectious diseases, including norovirus/rotavirus and
malaria, among others. Additionally, Blue Water Vaccines is
developing a Streptococcus pneumoniae (pneumococcus) vaccine
candidate, designed to specifically prevent the highly infectious
middle ear infections, known as Acute Otitis Media (AOM), in
children. For more information, visit
www.bluewatervaccines.com.
About Cincinnati Children’s
Cincinnati Children's ranks among the top three
in the nation in U.S. News & World Report's 2022-23 listing of
Best Children's Hospitals. A nonprofit, academic medical center
established in 1883, Cincinnati Children's is also one of the top
three recipients of pediatric research grants from the National
Institutes of Health. The medical center is internationally
recognized for improving child health and transforming delivery of
care through fully integrated, globally recognized research,
education, and innovation. Additional information about
technologies developed at Cincinnati Children's may be found
at Innovation.CincinnatiChildrens.org
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates; the failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations; delays and
uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any vaccine under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. BWV does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in BWV’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2021,
filed with the Securities and Exchange Commission (the “SEC”) on
March 31, 2022, and periodic reports filed with the SEC on or after
the date thereof. All of BWV’s forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date thereof.
Contact Information:Blue Water Media Relations513-620-4101Email:
media@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2023 to Jul 2024